DE60036403T2 - Verfahren zur Herstellung von gereinigter HCV-RNA durch Isolierung von Exosomen - Google Patents
Verfahren zur Herstellung von gereinigter HCV-RNA durch Isolierung von Exosomen Download PDFInfo
- Publication number
- DE60036403T2 DE60036403T2 DE60036403T DE60036403T DE60036403T2 DE 60036403 T2 DE60036403 T2 DE 60036403T2 DE 60036403 T DE60036403 T DE 60036403T DE 60036403 T DE60036403 T DE 60036403T DE 60036403 T2 DE60036403 T2 DE 60036403T2
- Authority
- DE
- Germany
- Prior art keywords
- hcv
- particles
- exosome
- preparation
- exosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 23
- 238000002955 isolation Methods 0.000 title abstract description 6
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 52
- 239000002245 particle Substances 0.000 claims abstract description 36
- 210000002381 plasma Anatomy 0.000 claims abstract description 23
- 238000000926 separation method Methods 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 27
- 239000011324 bead Substances 0.000 claims description 22
- 238000004113 cell culture Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000001085 differential centrifugation Methods 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000012228 culture supernatant Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 101710165845 CD81 protein Proteins 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000008188 pellet Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 238000001262 western blot Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 102100027221 CD81 antigen Human genes 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 102000055772 human CD81 Human genes 0.000 description 1
- 102000045407 human CD82 Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24251—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9927320 | 1999-11-18 | ||
| GBGB9927320.3A GB9927320D0 (en) | 1999-11-18 | 1999-11-18 | Exosome separation |
| PCT/IB2000/001801 WO2001036601A1 (en) | 1999-11-18 | 2000-11-20 | Method for the preparation of purified hcv rna by exosome separation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60036403D1 DE60036403D1 (de) | 2007-10-25 |
| DE60036403T2 true DE60036403T2 (de) | 2008-06-12 |
Family
ID=10864765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60036403T Expired - Lifetime DE60036403T2 (de) | 1999-11-18 | 2000-11-20 | Verfahren zur Herstellung von gereinigter HCV-RNA durch Isolierung von Exosomen |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7198923B1 (enExample) |
| EP (1) | EP1230347B1 (enExample) |
| JP (1) | JP4675017B2 (enExample) |
| AT (1) | ATE373084T1 (enExample) |
| AU (1) | AU1721801A (enExample) |
| CA (1) | CA2392075C (enExample) |
| CY (1) | CY1107521T1 (enExample) |
| DE (1) | DE60036403T2 (enExample) |
| DK (1) | DK1230347T3 (enExample) |
| ES (1) | ES2292489T3 (enExample) |
| GB (1) | GB9927320D0 (enExample) |
| PT (1) | PT1230347E (enExample) |
| WO (1) | WO2001036601A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9927320D0 (en) * | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
| US8021847B2 (en) | 2004-06-02 | 2011-09-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
| WO2005121369A2 (en) * | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
| ES2880460T3 (es) * | 2006-03-09 | 2021-11-24 | Aethlon Medical Inc | Eliminación extracorpórea de partículas microvesiculares |
| US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| US8617806B2 (en) * | 2008-01-25 | 2013-12-31 | Hansabiomed Ou | Method to measure and characterize microvesicles in the human body fluids |
| AU2009212543B2 (en) * | 2008-02-01 | 2015-07-09 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| US11266736B2 (en) | 2008-04-17 | 2022-03-08 | Vin De Bona Trading Company Pte Ltd | Method of painting micro vesicles |
| AU2009259893A1 (en) * | 2008-06-20 | 2009-12-23 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
| US9487837B2 (en) | 2008-10-06 | 2016-11-08 | Morehouse School Of Medicine | Exosome-mediated diagnosis of hepatitis virus infections and diseases |
| US10545149B2 (en) * | 2008-10-06 | 2020-01-28 | Morehouse School Of Medicine | Detection of HIV-related proteins in urine |
| JP2012507300A (ja) | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Ｒｎａパターンを評価する方法 |
| EP2350320A4 (en) * | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES |
| PT2419144T (pt) * | 2009-04-17 | 2019-09-16 | Univ Oxford Innovation Ltd | Composição para a administração de material genético |
| BRPI0900815A2 (pt) * | 2009-04-23 | 2010-12-28 | Sociedade Benef Israelita Bras Hospital Albert Einstein | método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro |
| DK2454588T3 (en) | 2009-07-16 | 2015-09-28 | Gen Hospital Corp | Nucleic acid |
| EP2475988B1 (en) | 2009-09-09 | 2018-11-14 | The General Hospital Corporation | Use of microvesicles in analyzing nucleic acid profiles |
| US20130029339A1 (en) | 2009-09-09 | 2013-01-31 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
| WO2011049059A1 (ja) * | 2009-10-22 | 2011-04-28 | 国立大学法人岐阜大学 | Ｒｎａ内包キャリア組成物 |
| CA2782284A1 (en) | 2009-11-30 | 2011-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods and systems for isolating, storing, and analyzing vesicles |
| AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| JP5755326B2 (ja) | 2010-06-11 | 2015-07-29 | 日立化成株式会社 | 腎機能の特徴を決定する方法 |
| WO2011156734A2 (en) * | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
| WO2012006476A2 (en) | 2010-07-07 | 2012-01-12 | Aethlon Medical, Inc. | Methods and compositions for quantifying exosomes |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| CA2817111C (en) | 2010-11-10 | 2019-03-05 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| CA2835641C (en) | 2011-05-11 | 2019-05-28 | Exosome Diagnostics, Inc. | Nucleic acid extraction from heterogeneous biological materials |
| WO2012170037A1 (en) | 2011-06-10 | 2012-12-13 | Hitachi Chemical Co., Ltd. | Vesicle capturing devices and methods for using same |
| CA2839896A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| EP3492606B1 (en) | 2011-08-22 | 2023-10-04 | Exosome Diagnostics, Inc. | Urine biomarkers |
| KR20140076571A (ko) * | 2011-09-22 | 2014-06-20 | 유니버시다드 데 로스 안데스 | 급성 신장 손상의 조기 모니터링, 진단 및/또는 예후 방법 |
| EP2776587A4 (en) | 2011-11-10 | 2015-07-15 | Exosome Diagnostics Inc | LIQUOR ASSAY |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| EP3299814A3 (en) * | 2012-07-19 | 2018-04-11 | Atlantic Cancer Research Institute | Method for the isolation of microvesicles |
| US11136627B2 (en) | 2012-08-30 | 2021-10-05 | Exosome Diagnostics, Inc. | Controls for nucleic acid assays |
| US20150252428A1 (en) | 2012-10-03 | 2015-09-10 | Exosome Diagnostics, Inc. | Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions |
| US20150233800A1 (en) | 2012-10-11 | 2015-08-20 | Vin-De-Bona Trading Company Pte Ltd | Method of painting microvesicles |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| BR112015016136A2 (pt) | 2013-01-03 | 2017-07-11 | Exosome Diagnostics Inc | métodos para isolar microvesículas |
| US12558316B2 (en) | 2013-03-13 | 2026-02-24 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
| AU2014244618A1 (en) | 2013-03-13 | 2015-10-08 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
| WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
| CA2920429C (en) | 2013-08-06 | 2021-11-16 | Exosome Diagnostics, Inc. | Urine biomarker cohorts, gene expression signatures, and methods of use thereof |
| BR112016004153A2 (pt) | 2013-08-28 | 2019-09-17 | Caris Life Sciences Switzerland Holdings Gmbh | "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero |
| US9958460B2 (en) * | 2013-10-24 | 2018-05-01 | Nanosomix, Inc. | Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders |
| EP3517959B1 (en) * | 2014-01-21 | 2021-05-05 | Morehouse School of Medicine | Exosome-mediated detection of hepatitis c infections |
| WO2015153732A2 (en) | 2014-04-01 | 2015-10-08 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
| US11268085B2 (en) | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| SG11201700146QA (en) | 2014-07-09 | 2017-02-27 | Exosome Diagnostics Inc | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| US20170227541A1 (en) | 2014-07-17 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
| US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
| WO2016077537A1 (en) | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
| EP3112474A1 (en) | 2015-06-29 | 2017-01-04 | Evonik Degussa GmbH | Method of detecting avian necrotic enteritis |
| US20180066262A1 (en) | 2015-03-09 | 2018-03-08 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| EA201890006A1 (ru) | 2015-06-10 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Применение экзосом для лечения болезни |
| WO2017004243A1 (en) | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides |
| US10941176B2 (en) | 2015-07-28 | 2021-03-09 | Caris Science, Inc. | Therapeutic oligonucleotides |
| JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
| EP3165926A1 (en) | 2015-11-06 | 2017-05-10 | Humanitas Mirasole S.p.A. | Method for characterization of cell specific microvesicles |
| JP2019513391A (ja) | 2016-04-15 | 2019-05-30 | エクソサム ダイアグノスティクス，インコーポレイティド | 未分化リンパ腫キナーゼ（ａｌｋ）核酸およびａｌｋ融合転写産物の血漿ベースの検出、並びに癌の診断と治療におけるそれらの使用 |
| WO2018057820A1 (en) | 2016-09-21 | 2018-03-29 | Predicine, Inc. | Systems and methods for combined detection of genetic alterations |
| WO2017181161A1 (en) | 2016-04-15 | 2017-10-19 | Predicine, Inc. | Systems and methods for detecting genetic alterations |
| KR102516168B1 (ko) | 2016-05-02 | 2023-03-30 | 엔코디아, 인코포레이티드 | 암호화 핵산을 사용한 거대분자 분석 |
| ES2908932T3 (es) | 2016-05-05 | 2022-05-04 | Exosome Diagnostics Inc | Perfilado de ácidos nucleicos de microvesícula y usos del mismo como características distintivas en diagnóstico de rechazo de trasplante renal |
| JP7037504B2 (ja) | 2016-05-13 | 2022-03-16 | エクソサム ダイアグノスティクス，インコーポレイティド | 生体液からの細胞外小胞の単離及びセルフリーｄｎａの同時単離のための自動及び手動方法 |
| IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
| EP3515453A1 (en) | 2016-09-22 | 2019-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
| US11396676B2 (en) | 2016-10-21 | 2022-07-26 | Exosome Diagnostics, Inc. | Sequencing and analysis of exosome associated nucleic acids |
| WO2018102162A1 (en) | 2016-11-30 | 2018-06-07 | Exosome Diagnostics, Inc. | Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients |
| GB2559319B (en) | 2016-12-23 | 2019-01-16 | Cs Genetics Ltd | Reagents and methods for the analysis of linked nucleic acids |
| US20200149036A1 (en) | 2017-01-02 | 2020-05-14 | Exosome Diagnostics, Inc. | Methods to distinguish rna and dna in a combined preparation |
| ES2944359T3 (es) | 2017-05-12 | 2023-06-20 | Evonik Operations Gmbh | Procedimiento de detección de enfermedades inducidas por C. perfringens en una bandada de aves |
| WO2018213392A1 (en) | 2017-05-17 | 2018-11-22 | Exosome Diagnostics, Inc. | Microvesicle nucleic acids and/or proteins and uses thereof as markers of renal transplant rejection |
| EP3652315A4 (en) * | 2017-07-12 | 2021-09-01 | Exosome Diagnostics, Inc. | METHODS FOR ISOLATION AND ENRICHMENT OF EXTRACELLULAR VESICLE POPULATIONS DERIVED FROM BIOFLUIDS, AND ASSOCIATED METHODS OF USE |
| US11345957B2 (en) | 2017-07-18 | 2022-05-31 | Exosome Diagnostics, Inc. | Methods of treating glioblastoma in a subject informed by exosomal RNA signatures |
| MX2020004559A (es) | 2017-10-31 | 2020-10-05 | Encodia Inc | Kits para análisis utilizando codificación y/o etiqueta de ácido nucleico. |
| US20200339987A1 (en) | 2017-11-09 | 2020-10-29 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining expression of the lect2 gene |
| CN110123838B (zh) * | 2018-02-02 | 2022-04-01 | 上海睿泰生物科技股份有限公司 | 负载白藜芦醇的人多能干细胞外泌体及其制备方法与用途 |
| CN110123841A (zh) * | 2018-02-09 | 2019-08-16 | 上海市第六人民医院 | 负载白藜芦醇的人多能干细胞外泌体在制备治疗生殖系统疾病药物的用途 |
| KR20200128413A (ko) | 2018-03-02 | 2020-11-12 | 에보니크 오퍼레이션즈 게엠베하 | 오보트랜스페린을 결정함으로써 동물에서의 장 장벽 기능상실을 검출하기 위한 시험관내 방법 |
| WO2019236853A1 (en) | 2018-06-06 | 2019-12-12 | Exosome Diagnostics, Inc. | Methods for developing urine biomarkers and for detecting bladder cancer |
| EP3884045B1 (en) | 2018-11-20 | 2023-01-11 | Exosome Diagnostics, Inc. | Methods for internal controls of microvesicle isolations |
| BR112021011158A2 (pt) | 2018-12-14 | 2021-08-31 | Evonik Operations Gmbh | Método in vitro para detectar disbiose intestinal aviária, uso do dito método e uso de isoleucil-arginina ou isômeros desta |
| EP3963070A4 (en) | 2019-04-30 | 2023-02-22 | Encodia, Inc. | METHODS OF PREPARATION OF ANALYTES AND RELATED KITS |
| US12493029B2 (en) | 2019-09-18 | 2025-12-09 | Exosome Diagnostics, Inc. | Compositions, methods, and kits for the isolation of extracellular vesicles |
| US20230135456A1 (en) | 2020-04-13 | 2023-05-04 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
| TW202214851A (zh) * | 2020-10-07 | 2022-04-16 | 國立中央大學 | 外泌體核酸萃取方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT54896A (en) * | 1989-03-17 | 1991-04-29 | Chiron Corp | Process for producing aquous diagnosticum and vaccine of nanbv |
| US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
| JPH05508762A (ja) | 1990-04-03 | 1993-12-09 | サウスウエスト・ファウンデイション・フォー・バイオメディカル・リサーチ | 精製されたｈｃｖならびにｈｃｖタンパク質およびペプチド |
| GB9416671D0 (en) | 1994-08-17 | 1994-10-12 | Biocine Spa | Assay |
| EP0841945B1 (en) * | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
| GB9517926D0 (en) | 1995-09-01 | 1995-11-01 | Biocine Spa | Binding protein |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| WO1999018198A1 (en) | 1997-10-06 | 1999-04-15 | Chiron S.P.A. | Hepatitis c receptor protein cd81 |
| CA2305715A1 (en) * | 1997-11-06 | 1999-05-20 | Innogenetics N.V. | Host derived proteins binding hcv: medical, diagnostic and purification use |
| GB9927320D0 (en) * | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
-
1999
- 1999-11-18 GB GBGB9927320.3A patent/GB9927320D0/en not_active Ceased
-
2000
- 2000-11-20 US US10/130,467 patent/US7198923B1/en not_active Expired - Lifetime
- 2000-11-20 DE DE60036403T patent/DE60036403T2/de not_active Expired - Lifetime
- 2000-11-20 EP EP00979837A patent/EP1230347B1/en not_active Expired - Lifetime
- 2000-11-20 ES ES00979837T patent/ES2292489T3/es not_active Expired - Lifetime
- 2000-11-20 CA CA2392075A patent/CA2392075C/en not_active Expired - Lifetime
- 2000-11-20 JP JP2001538480A patent/JP4675017B2/ja not_active Expired - Fee Related
- 2000-11-20 AU AU17218/01A patent/AU1721801A/en not_active Abandoned
- 2000-11-20 DK DK00979837T patent/DK1230347T3/da active
- 2000-11-20 WO PCT/IB2000/001801 patent/WO2001036601A1/en not_active Ceased
- 2000-11-20 AT AT00979837T patent/ATE373084T1/de active
- 2000-11-20 PT PT00979837T patent/PT1230347E/pt unknown
-
2007
- 2007-01-30 US US11/699,925 patent/US7807438B2/en not_active Expired - Fee Related
- 2007-12-07 CY CY20071101559T patent/CY1107521T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7198923B1 (en) | 2007-04-03 |
| AU1721801A (en) | 2001-05-30 |
| DK1230347T3 (da) | 2007-11-05 |
| JP2003514523A (ja) | 2003-04-22 |
| JP4675017B2 (ja) | 2011-04-20 |
| CA2392075A1 (en) | 2001-05-25 |
| CY1107521T1 (el) | 2013-03-13 |
| WO2001036601A1 (en) | 2001-05-25 |
| US20070254351A1 (en) | 2007-11-01 |
| EP1230347B1 (en) | 2007-09-12 |
| CA2392075C (en) | 2011-01-04 |
| PT1230347E (pt) | 2007-12-20 |
| GB9927320D0 (en) | 2000-01-12 |
| US7807438B2 (en) | 2010-10-05 |
| ATE373084T1 (de) | 2007-09-15 |
| DE60036403D1 (de) | 2007-10-25 |
| ES2292489T3 (es) | 2008-03-16 |
| EP1230347A1 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7198923B1 (en) | Method for the preparation of purified HCV RNA by exosome separation | |
| DE69131882T2 (de) | Asiloglycoproteine des hepatitis c-virus | |
| US4390623A (en) | Serum-free and mitogen-free T-cell growth factor and process for making same | |
| JP2001504337A (ja) | Ｃ型肝炎ウイルス様粒子の合成および精製 | |
| Stevens et al. | Localization of the Mycoplasma pneumoniae cytadherence-accessory proteins HMW1 and HMW4 in the cytoskeletonlike Triton shell | |
| JP2003514523A5 (enExample) | ||
| CA1193210A (en) | Human hepatoma derived cell line, process for preparation thereof, and uses therefor | |
| EP0049611B2 (en) | A T-cell growth factor, and a process of producing the same | |
| DE69836499T2 (de) | Virus mit membranmutationen für ein witsspektrum und deren verwendung als vakzinsubstrat | |
| EP0279460A1 (de) | Virusantigen, Verfahren zu seiner Gewinnung und Anwendung in Diagnose und Therapie (Impfstoff) | |
| EP0124896B1 (de) | Verfahren zur Gewinnung von Viren bzw. Virusantigenen und deren Anwendung in Diagnose und Therapie (Impfstoff) | |
| EP1124575A1 (de) | Verfahren zur herstellung eines antiviralen mittels | |
| DE3619902A1 (de) | Cmv-dna-strukturen, expressionsvektor dafuer, cmv-proteinstrukturen und deren verwendung | |
| Lucas et al. | The regeneration and division of mouse L-cell karyoplasts | |
| Martin | The biochemistry of viruses | |
| EP0180012A1 (de) | Immunogene Polypeptidsequenz des Hepatitis B-Virus | |
| DE60118397T2 (de) | Komplex aus den teilen des hepatitis c virus und lipoprotein geringer dichte, verfahren zu seiner herstellung und anwendungen | |
| McLean et al. | Cardiac-like action potentials recorded from spontaneously-contracting structures induced in post-nodal pieces of chick blastoderm exposed to an RNA-enriched fraction from adult heart | |
| Weiss et al. | Comparison of the effects of coxsackievirus A9 and of actinomycin D on the nucleolar ultrastructure of monkey kidney cells | |
| Mori et al. | Formation of heterophile antibodies by human tonsilar lymphocytes: I. In vitro stimulation with heterologous antigens | |
| Revoltella et al. | Spontaneous fusion and formation of hybrids between C1300 neuroblastoma cells and lymphoid cells in mixed cultures | |
| Loyter et al. | [41] Implantation of Isolated Carriers and receptors into living cells by Sendai virus envelope-mediated fusion | |
| DE69133382T3 (de) | Asialoglycoproteine des Hepatitis C-Virus | |
| Duda et al. | Sindbis virus receptor protein of BHK cells | |
| Raghow | Studies on Virus Replication in Cultured Insect and Mammalian Cells: I. Ultra-Structural Development and Virus-Specific Protein Synthesis in Togavirus-Infected Mammalian and Mosquito Cells: A Comparative Study II. Ultrastructural Development of a Nuclear Polyhedrosis Virus in Silkworm Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |